Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors

Abstract

Glycogen storage disease type II (GSDII) is caused by a lack of functional lysosomal acid α-glucosidase (GAA). Affected individuals store glycogen in lysosomes beginning during gestation, ultimately resulting in fatal hypertrophic cardiomyopathy and respiratory failure. We have assessed the utility of recombinant adeno-associated virus (rAAV) vectors to restore GAA activity in vivo in a mouse model of GSDII (Gaa−/−). A single systemic administration of a rAAV serotype 1 (rAAV1) vector to neonate animals resulted in restored cardiac GAA activity to 6.4 times the normal level (mean=641±190% of normal (Gaa+/+) levels with concomitant glycogen clearance) at 11 months postinjection. Greater than 20% of normal levels of GAA activity were also observed in the diaphragm and quadriceps muscles. Furthermore, functional correction of the soleus skeletal muscle was also observed compared to age-matched untreated Gaa−/− control animals. These results demonstrate that rAAV1 vectors can mediate sustained therapeutic levels of correction of both skeletal and cardiac muscles in a model of fatal cardiomyopathy and muscular dystrophy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Baudhin P, Hers HG . An electron microscopic and biochemical study of type II glycogenosis. Lab Invest 1964; 13: 1139–1152.

    Google Scholar 

  2. Hirschhorn R, Reuser AJJ . Glycogen storage disease II: acid-alpha glucosidase (acid maltase) deficiency. In: Scriver et al (eds). The Metabolic and Molecular Bases of Inherited Diseases. McGraw Hill: New York, 2000, pp 3389–3420.

    Google Scholar 

  3. Hers HG . Alpha-glucosidase deficiency in generalized glycogen storage disease (Pompe's disease). Biochem J 1963; 86: 11–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Raben N, Plotz P, Byrne BJ . Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2002; 2: 145–166.

    Article  CAS  PubMed  Google Scholar 

  5. Reuser AJ et al. Glycogenosis type II (acid maltase deficiency). Muscle Nerve 1995; 3: S61–S69.

    Article  CAS  PubMed  Google Scholar 

  6. Flotte TR et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003; 14: 1079–1088.

    Article  CAS  PubMed  Google Scholar 

  7. Flotte TR et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004; 15: 93–128.

    Article  PubMed  Google Scholar 

  8. Manno CS et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963–2972.

    Article  CAS  PubMed  Google Scholar 

  9. Moss RB et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004; 125: 509–521.

    Article  PubMed  Google Scholar 

  10. Chao H et al. Sustained and complete phenotype correction of hemophilia b mice following intramuscular injection of aav1 serotype vectors. Mol Ther 2001; 4: 217–222.

    Article  CAS  PubMed  Google Scholar 

  11. Gao G et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci USA 2003; 100: 6081–6086.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gao GP et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854–11859.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gregorevic P et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10: 828–834.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Rabinowitz JE et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Rutledge EA, Halbert CL, Russell DW . Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998; 72: 309–319.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Zabner J et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74: 3852–3858.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Champion HC et al. Robust adenoviral and adeno-associated viral gene transfer to the in vivo murine heart: application to study of phospholamban physiology. Circulation 2003; 108: 2790–2797.

    Article  CAS  PubMed  Google Scholar 

  18. Hauck B, Xiao W . Characterization of tissue tropism determinants of adeno-associated virus type 1. J Virol 2003; 77: 2768–2774.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Xiao W et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 73: 3994–4003.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Lin CY et al. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency. Gene Therapy 2002; 9: 554–563.

    Article  CAS  PubMed  Google Scholar 

  21. Rucker M et al. Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: pompe disease. Development 2004; 131: 3007–3019.

    Article  CAS  PubMed  Google Scholar 

  22. Sun B et al. Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector. Mol Ther 2003; 7: 467–477.

    Article  CAS  PubMed  Google Scholar 

  23. Raben N et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 1998; 273: 19086–19092.

    Article  CAS  PubMed  Google Scholar 

  24. Fraites Jr TJ et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002; 5: 571–578.

    Article  CAS  PubMed  Google Scholar 

  25. Blankinship MJ et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 2004; 10: 671–678.

    Article  CAS  PubMed  Google Scholar 

  26. Zhu T et al. Profound cardiac and whole-body functional recovery in heart failure/muscular dystrophy hamsters by systemic delivery of AAV8 vectors via i.v. or i.p. route. Xth Parvovirus Workshop, 2004.

  27. Sun B et al. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther 2005; 11: 57–65.

    Article  CAS  PubMed  Google Scholar 

  28. Loser P et al. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 1998; 72: 180–190.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Ding E et al. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther 2002; 5: 436–446.

    Article  CAS  PubMed  Google Scholar 

  30. Raben N et al. Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Genet 2001; 10: 2039–2047.

    Article  CAS  PubMed  Google Scholar 

  31. Raben N et al. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther 2002; 6: 601–608.

    Article  CAS  PubMed  Google Scholar 

  32. Raben N et al. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther 2005; 11: 48–56.

    Article  CAS  PubMed  Google Scholar 

  33. Zolotukhin S et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002; 28: 158–167.

    Article  CAS  PubMed  Google Scholar 

  34. Sands MS, Barker JE . Percutaneous intravenous injection in neonatal mice. Lab Anim Sci 1999; 49: 328–330.

    CAS  PubMed  Google Scholar 

  35. Cresawn KO et al. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II. Hum Gene Ther 2005; 16: 68–80.

    Article  CAS  PubMed  Google Scholar 

  36. Mingozzi F et al. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol 2002; 76: 10497–10502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the University of Florida Powell Gene Therapy Center Vector Core Laboratory, which produced some of the rAAV vectors used in this study. This work was supported by grants from the National Institutes of Health (NHLBI P01 HL59412, NIDDK P01 DK58327), the Muscular Dystrophy Association, and the American Heart Association Florida and Puerto Rico Affiliate (KOC, TJF, CAP) and National Center (CM). BJB, The Johns Hopkins University, and the University of Florida could be entitled to patent royalties for inventions described in this manuscript.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mah, C., Cresawn, K., Fraites, T. et al. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther 12, 1405–1409 (2005). https://doi.org/10.1038/sj.gt.3302550

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302550

Keywords

This article is cited by

Search

Quick links